Log in
NASDAQ:MEDP

Medpace Stock Forecast, Price & News

$121.70
-3.00 (-2.41 %)
(As of 11/25/2020 12:00 AM ET)
Add
Compare
Today's Range
$121.52
Now: $121.70
$124.24
50-Day Range
$109.38
MA: $119.25
$126.86
52-Week Range
$58.72
Now: $121.70
$144.49
Volume180,652 shs
Average Volume326,677 shs
Market Capitalization$4.35 billion
P/E Ratio37.22
Dividend YieldN/A
Beta1.35
Medpace Holdings, Inc., a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It also provides clinical development services; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. The company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is headquartered in Cincinnati, Ohio.
Read More
Medpace logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.3Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.19 out of 5 stars


Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MEDP
CUSIPN/A
Phone513-579-9911
Employees3,400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$860.97 million
Cash Flow$3.90 per share
Book Value$22.13 per share

Profitability

Net Income$100.44 million

Miscellaneous

Market Cap$4.35 billion
Next Earnings Date2/22/2021 (Estimated)
OptionableOptionable
$121.70
-3.00 (-2.41 %)
(As of 11/25/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MEDP News and Ratings via Email

Sign-up to receive the latest news and ratings for MEDP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Medpace (NASDAQ:MEDP) Frequently Asked Questions

How has Medpace's stock price been impacted by Coronavirus (COVID-19)?

Medpace's stock was trading at $83.64 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, MEDP shares have increased by 45.5% and is now trading at $121.70.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Medpace?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medpace in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Medpace
.

What stocks does MarketBeat like better than Medpace?

Wall Street analysts have given Medpace a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Medpace wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Medpace's next earnings date?

Medpace is scheduled to release its next quarterly earnings announcement on Monday, February 22nd 2021.
View our earnings forecast for Medpace
.

How were Medpace's earnings last quarter?

Medpace Holdings, Inc. (NASDAQ:MEDP) posted its quarterly earnings data on Saturday, October, 31st. The company reported $1.09 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $1.07 by $0.02. The firm earned $230.37 million during the quarter, compared to analyst estimates of $223.56 million. Medpace had a net margin of 13.87% and a return on equity of 17.67%. Medpace's quarterly revenue was up 6.5% on a year-over-year basis. During the same quarter last year, the firm earned $0.71 EPS.
View Medpace's earnings history
.

What guidance has Medpace issued on next quarter's earnings?

Medpace updated its FY20 earnings guidance on Monday, October, 26th. The company provided earnings per share (EPS) guidance of $3.62-3.83 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.95. The company issued revenue guidance of $880-920 million, compared to the consensus revenue estimate of $903.50 million.

What price target have analysts set for MEDP?

6 analysts have issued 1 year price objectives for Medpace's shares. Their forecasts range from $75.00 to $135.00. On average, they expect Medpace's share price to reach $103.00 in the next twelve months. This suggests that the stock has a possible downside of 15.4%.
View analysts' price targets for Medpace
.

Are investors shorting Medpace?

Medpace saw a increase in short interest in October. As of October 30th, there was short interest totaling 815,400 shares, an increase of 25.8% from the October 15th total of 648,100 shares. Based on an average daily volume of 354,600 shares, the days-to-cover ratio is currently 2.3 days. Approximately 3.0% of the shares of the company are sold short.
View Medpace's Short Interest
.

Who are some of Medpace's key competitors?

What other stocks do shareholders of Medpace own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Medpace investors own include NVIDIA (NVDA), Exact Sciences (EXAS), Square (SQ), Baidu (BIDU), JD.com (JD), Advanced Micro Devices (AMD), Bilibili (BILI), Alibaba Group (BABA), Cisco Systems (CSCO) and Intuitive Surgical (ISRG).

Who are Medpace's key executives?

Medpace's management team includes the following people:
  • Dr. August James Troendle, Chairman, Pres & CEO (Age 64, Pay $592.56k)
  • Mr. Jesse J. Geiger, CFO & COO of Laboratory Operations (Age 46, Pay $418.98k)
  • Ms. Susan E. Burwig, Exec. VP of Operations (Age 57, Pay $633.22k)
  • Mr. Stephen P. Ewald, Chief Compliance Officer, Gen. Counsel & Corp. Sec. (Age 51, Pay $415.79k)
  • Mr. Todd Meyers, VP of Bus. Devel. & Marketing
  • Mr. Weimin Gai MS, Sr. VP of Biometrics
  • Mr. Daniel O'Leary, Sr. VP of Medical Department
  • John T. Wynne, Sr. VP of Commercial Operations & Clinical Pharmacology Unit
  • Mr. Kevin M. Brady, Exec. Director of Fin.

When did Medpace IPO?

(MEDP) raised $150 million in an initial public offering (IPO) on Thursday, August 11th 2016. The company issued 7,000,000 shares at a price of $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers.

What is Medpace's stock symbol?

Medpace trades on the NASDAQ under the ticker symbol "MEDP."

Who are Medpace's major shareholders?

Medpace's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (10.08%), Wasatch Advisors Inc. (6.35%), Fuller & Thaler Asset Management Inc. (2.43%), State Street Corp (2.35%), Pendal Group Limited (2.31%) and Boston Trust Walden Corp (1.15%). Company insiders that own Medpace stock include August J Troendle, Jesse J Geiger, Medpace Investors, Llc, Stephen P Ewald and Susan E Burwig.
View institutional ownership trends for Medpace
.

Which major investors are selling Medpace stock?

MEDP stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Wasatch Advisors Inc., Pendal Group Limited, Acadian Asset Management LLC, Principal Financial Group Inc., Federated Hermes Inc., Fisher Asset Management LLC, and AQR Capital Management LLC. Company insiders that have sold Medpace company stock in the last year include August J Troendle, Jesse J Geiger, Medpace Investors, Llc, Stephen P Ewald, and Susan E Burwig.
View insider buying and selling activity for Medpace
.

Which major investors are buying Medpace stock?

MEDP stock was acquired by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., UBS Asset Management Americas Inc., CI Investments Inc., Point72 Asset Management L.P., Jupiter Asset Management Ltd., Castleark Management LLC, JPMorgan Chase & Co., and Ziegler Capital Management LLC.
View insider buying and selling activity for Medpace
.

How do I buy shares of Medpace?

Shares of MEDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Medpace's stock price today?

One share of MEDP stock can currently be purchased for approximately $121.70.

How big of a company is Medpace?

Medpace has a market capitalization of $4.35 billion and generates $860.97 million in revenue each year. The company earns $100.44 million in net income (profit) each year or $3.02 on an earnings per share basis. Medpace employs 3,400 workers across the globe.

What is Medpace's official website?

The official website for Medpace is www.medpace.com.

How can I contact Medpace?

Medpace's mailing address is 5375 MEDPACE WAY, CINCINNATI OH, 45227. The company can be reached via phone at 513-579-9911 or via email at [email protected]

This page was last updated on 11/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.